26 results about "Chronic stressor" patented technology

The invention relates to bacteria of the species Lactobacillus paracasei and / or compositions comprising Lactobacillus paracasei for use in preventing and / or treating a mental illness, a symptom affecting mental health and / or a condition associated with chronic stress, in a mammal. The invention further relates to methods and uses of said bacteria of the species Lactobacillus paracasei and / or compositions. The invention can be applied in restoring, maintaining, and / or promoting mental (including cognitive) health and has potential applications, inter alia, in the area of dietary and food supplements, medicaments and pharmaceuticals.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of drugs for improving sleep disorder and treating mood disorder or cognitive disorder. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by mass: 20-30 parts of lycium ruthenicum, 30-40 parts of nitraria fruit, 15-25 parts of gastrodia elata, 13-25 parts of hyperforin perforatum and 2-6 parts of lycopene. The traditional Chinese medicine composition provided by the invention is prepared from lycium ruthenicum, nitraria fruit, gastrodia elata, hyperforin perforatum and lycopene according to a specific ratio, and the composition can effectively relieve anxiety behaviors of chronic stress bound anxiety model mice through ways of resisting oxidation and inflammation, regulating expression of neurotransmitters and the like, prolong sleep time and improve sleep quality. The learning ability and the memory ability of cognitive impairment mice induced by scopolamine are improved, and the neuron density of brain tissues is increased, so that the neuroprotective effect is achieved.

This invention relates to a novel use of propargylcysteine ​​in the preparation of anti-mastopathy drugs. The invention discovers that S-propargylcysteine ​​can improve E2 / P imbalance by regulating HPO axis function and inhibiting abnormal activation of the GnRH-sex hormone axis; it also reduces the inflammatory microenvironment by inhibiting the release of inflammatory factors; ultimately, it downregulates ER / PR-mediated proliferation signals and inhibits PCNA expression locally in the breast. Through multi-target regulation of neuroendocrine, inflammatory responses, and proliferation-related signaling pathways, it effectively alleviates breast hyperplasia and its associated chronic stress-induced depressive-like behaviors, thus exerting anti-mastopathy and therapeutic effects on breast hyperplasia complicated with depression.

The application provides application of dimethyl itaconate in prevention and treatment of chronic stress-induced anxiety. The application finds that dimethyl itaconate can inhibit excessive activation of microglial cells in a stress state, improve mitochondrial structure and function abnormalities of the microglial cells, and reduce expression of a lysosome marker CD68, so as to inhibit central nervous inflammation, maintain central nervous immune homeostasis, prevent and relieve anxiety-like behavior induced by chronic stress, and effectively prevent and relieve occurrence and development of chronic stress-induced anxiety (generalized anxiety disorder).

The present invention provides a multiomics approach, which integrate single-cell RNA-sequencing (scRNA-seq) and spatiotemporal transcriptomics (ST) offering potential for dissecting transcriptional networks and revealing cell-cell interactions involved in biomolecular pathomechanisms. The present invention also provides a multimodal approach combining high-throughput scRNA-seq and ST to elucidate XLRS-specific transcriptomic signatures in two XLRS-like models with retinal splitting phenotypes, including genetically engineered (Rs1emR209C) mice and patient-derived retinal organoids harboring the same patient-specific p.R209C mutation. Through multiomics transcriptomic analysis, the endoplasmic reticulum (ER) stress / eIF2 signaling, mTOR pathway, and the regulation of eIF4 and p70S6K pathways as chronically enriched and highly conserved disease pathways between two XLRS-like models are identified. Western blots and proteomics analysis validated the occurrence of unfolded protein responses, chronic eIF2α signaling activation, and chronic ER stress-induced apoptosis. Furthermore, therapeutic targeting of the chronic ER stress / eIF2α pathway activation synergistically enhanced the efficacy of AAV mediated RS1 gene delivery, ultimately improving bipolar cell integrity, postsynaptic transmission, disorganized retinal architecture and electrophysiological responses. Collectively, the complex transcriptomic signatures obtained from Rs1emR209C mice and patient-derived retinal organoids using the multiomics approach provide opportunities to unravel potential therapeutic targets for incurable retinal diseases, such as XLRS.

The application discloses a mouse vitiligo induction model based on chronic stress factors, wherein different kinds of stress factors capable of triggering stress response of animals are applied to stimulate the mouse periodically within a certain time period, so as to prevent the mouse from producing habitual response to the stress source and to promote the mouse to become white and the tail epidermis to be flaky. The technical method is different from the existing vitiligo model method, is based on the mechanism of occurrence and development of vitiligo observed in the clinic, and promotes the mouse to truly develop the vitiligo phenomenon from the whole instead of simulating the disease evolution locally. Compared with the existing vitiligo promoting mechanism, the effect is more stable and the authenticity is higher. The technical method is based on the objective fact that the clinical vitiligo patients often combine anxiety and depression to design the stress factors, and considers that the stress factors and the occurrence and development of vitiligo may be inter-caused and viciously circulate, namely, the adverse life events as the stress factors cause the damage and dysfunction of the melanin synthesis system at the micro level and form the vitiligo change at the macro level.

The present application relates to a Pediococcus acidilactici capable of reducing the activation of hippocampal microglia cells and its application, belonging to the technical field of microorganisms. The Pediococcus acidilactici described in the present application is Pediococcus acidilactici CCFM1344, which was preserved in the Guangdong Microbial Culture Collection Center on September 12, 2023, with the preservation number GDMCC NO.63800. The preservation address is Building 59, 5th Floor, Guangdong Microbial Institute, 100 Middle Martyrs Road, Guangzhou. The Pediococcus acidilactici described in the present application can inhibit the over-activation of microglia cells caused by chronic stress, reduce the concentration of pro-inflammatory factors in the hippocampus of the brain, thereby relieving the activation of microglia cells in the hippocampus of the brain caused by chronic stress, and has excellent application prospects.

The invention relates to a preparation method and application of a lactating cow premix for improving a chronic stress state, and the lactating cow premix comprises the following components in percentage by mass: 25-40% of a carrier, 0.01-0.05% of an antioxidant, 2-8% of vitamins, 40-60% of minerals, 0.5-2% of probiotics, 1-5% of saccharomyces cerevisiae, 5-10% of lysine, 0.01-0.05% of chromium methionine and 2-5% of curcumin. The preparation method comprises the following steps: weighing the components in proportion, adding the components into a mixer, mixing for 20-40 minutes, packaging, and inspecting. The lactating dairy cow premix for improving the chronic stress state can effectively relieve the chronic stress condition of dairy cows, reduce the probability that the dairy cows suffer from mastitis and digestive tract diseases in the stress period, improve the resistance and immune function of the lactating dairy cows, increase the milk yield and improve the milk quality, and is balanced in formula nutrition, simple in preparation method and low in cost. The feed additive can be directly added into feed and has a wide application prospect.

The application discloses a vitamin D binding protein gene conditional knockout mouse model and application thereof. It is found that the mouse with the vitamin D binding protein specifically knocked out in microglial cells can resist chronic stress-induced depressive behavior; it is indicated that the vitamin D binding protein in the microglial cells is a key factor for the occurrence and development of depressive behavior; by knocking out the vitamin D binding protein in the microglial cells, a significant effect of resisting depressive behavior can be achieved; the vitamin D binding protein in the microglial cells can be used as a drug target for screening drugs for treating depression, and the vitamin D binding protein inhibitor in the microglial cells can be used for preparing the drugs for treating depression. The application opens a new direction for in-depth research on depression and provides more choices for clinical treatment of depression, and has very important theoretical and practical significance.

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

Provided are methods of determining risk for chronic stress and stroke. More specifically, provided is an early prognostic index that can be used to predict chronic stress and stroke risk. There is provided a method of evaluating the risk of developing chronic stress and stroke, the method including obtaining a biological sample from an individual; measuring the levels of a set of biomarkers in the biological sample obtained from the individual; measuring the levels of a set of clinical markers of the individual; using a computer to programmatically generate an index based on the levels of biomarker in the biological sample obtained from the individual in combination with levels of the individual's clinical marker; and using the index to identify a likelihood that the individual will experience chronic stress and stroke.

The invention relates to the technical field of biological medicine, in particular to a 11 beta-HSD1 targeting protein degradation targeting chimera as well as a preparation method and application thereof. The protein degradation targeting chimera is a compound as shown in a formula I or a pharmaceutically acceptable salt, in the formula I, X is a ligand of 11 beta-HSD1 protein, Z is a ligand of E3 ligase, and Y is a connecting part of X and Z; the protein degradation targeting chimera can effectively reduce the protein level and improve cognitive disorder of AD model mice and depressive disorder of chronic stress model mice.

Disclosed herein are compositions and methods for treating, preventing, reducing, modulating, or alleviating the detrimental effects of stress, symptoms of stress, or chronic stress by providing compositions and carriers. The method may comprise, for example, administering a compound of a therapeutically effective plant extract. The compositions and methods are capable of modulating the mGlu2 and / or mGlu3 receptors.

The invention relates to the technical field of medical data management, in particular to a hypertensive patient stress source management method based on detailed nursing. According to the method, after blood pressure stress points are screened out, short-term blood pressure stress points and chronic blood pressure stress points are screened out by quantifying short-term stress stimulation conformity, and then the blood pressure short-term stress influence degree of a patient is obtained through the systolic pressure change rate. A complete chronic stimulation stage is determined through a splitting and combining method, and the blood pressure chronic stress influence degree of each patient can be obtained by analyzing the similarity degree between different time periods. Patients can be classified based on the two stress features, and in the result of the first classification, the similarity degree of the complete chronic stimulation stage continues to be considered for further classification. According to the method, the blood pressure stress characteristics of the patient in a short term and a long term are determined based on the change trend of systolic pressure and diastolic pressure, the patient can be classified in detail, and effective management and targeted nursing of detailed nursing of the hypertensive patient are facilitated.

The invention relates to application of a medicine for inhibiting glioma progression promoted by chronic pressure stress, and relates to the technical field of biological medicine, chronic pressure stress is proved to be a key risk factor for promoting glioma progression, but a cell molecular mechanism behind the chronic pressure stress is not clear yet. Therefore, a targeting drug capable of specifically intervening in the process is lacked clinically. Existing immunotherapy such as adoptive NK cell therapy is poor in effect in glioma clinical tests, it is prompted that pressure stress possibly induces a strong immunosuppression microenvironment, and the technical scheme with a C5aR inhibitor Avacopan as the core is provided. According to the means, the activity of a key node C5aR1 in a pressure stress signal channel is blocked through a pharmacological method, functional inhibitory stress-related macrophages (SAMs) are cleared in a targeted manner, so that immunosuppression is reversed, glioma growth driven by chronic pressure stress can be selectively inhibited, and a synergistic interaction effect with an NK cell therapy is shown in an in-vivo experiment.

This invention provides a method, system, storage medium, and device for grading chronic stress emotional states. The method includes continuously and non-interfering acquisition of ultra-low frequency physiological data such as heart rate and blood oxygen saturation via a wrist-worn device; extraction of characteristic indicators such as diurnal heart rate variation, recovery time, heart rate entropy, and low blood oxygen duration; simultaneous acquisition of psychological scale and personality trait data, construction of an associated database, and analysis of patterns; and training a machine learning model based on selected physiological features and psychological grading labels to achieve automatic grading of chronic stress states (mild, moderate, and severe). This invention effectively characterizes changes in autonomic nervous function under long-term stress by utilizing ultra-low frequency physiological rhythm characteristics and combines them with personality traits for personalized modeling, solving the problem of objectively, continuously, and accurately assessing the chronic stress state of individuals in real high-risk work environments.

The present disclosure provides methods for treating or alleviating symptoms of a disease, disorder, or condition related to excess androgen or stress-induced skin changes in a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Other aspects relate to methods for providing anti-oxidative stress, anti-inflammatory and anti-aging benefits for the skin to a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Surprisingly, it has been found that spironolactone may be topically administered with reduced adverse effect compared to systemic administration of the same medication.

The invention discloses application of an NRGN gene in preparation of a medicine for treating chronic visceral pain. The medicine is used for treating the chronic visceral pain by inhibiting expression of the NRGN gene in CaMKII alpha positive neurons of a V layer of an islet cortex cerebral region. Single cell sequencing finds that in a chronic visceral pain model induced by chronic pressure stress, the expression of the positive neuron NRGN of the V layer CaMKII alpha in the islet cortex brain region is remarkably increased, the visceral pain behavior of a model mouse can be remarkably improved by stereotactic injection of the shRNA virus vector of the targeted NRGN, and a new strategy is provided for central targeted therapy of the chronic visceral pain.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

This invention relates to the field of medical data management technology, specifically to a method for managing stressors in hypertensive patients based on meticulous nursing care. After identifying blood pressure stress points, this method quantifies the conformity of short-term stress stimuli to identify both short-term and chronic blood pressure stress points. The impact of short-term blood pressure stress on the patient is then obtained through the rate of change in systolic blood pressure. Complete chronic stress phases are determined through splitting and merging methods, and the similarity between different time periods is analyzed to obtain the chronic blood pressure stress impact on each patient. Patients can be classified based on these two stress characteristics. In the results of the first classification, the similarity of the complete chronic stress phases is further considered for further classification. This invention determines the short-term and long-term blood pressure stress characteristics of patients based on the trends in systolic and diastolic blood pressure, enabling meticulous patient classification and facilitating effective management and targeted nursing care for hypertensive patients.

The application discloses a composition with the effects of balancing cortisol, balancing pressure and soothing and application thereof, and belongs to the technical field of functional skin care products. The composition is prepared by compounding paeonia root extract, gardenia fruit extract, mint extract, albizzia lebbeck seed extract, anemarrhena asphodeloides root extract, ginkgo leaf extract and dipeptide-1 in specific mass fractions. The components in the composition have a synergistic effect, can intervene in the excessive activation of the HPA axis from the upstream, balance the cortisol level from the root cause, relieve chronic stress, can significantly reduce the symptoms of skin sensitivity and the level of inflammatory factors, effectively inhibit the inflammatory response and soothe the skin sensitivity. The application solves the technical defects of the prior art that the existing products only have the effect of surface soothing and cannot block the continuous influence of stress on the skin, and provides a solution that takes both the symptoms and the root cause into consideration for the stress-related skin problems.

Disclosed are use of an indole 2,3-dioxygenase (IDO1) inhibitor albiflorin (paeoniflorin), or a pharmaceutically acceptable salt thereof, or an extract or composition containing a therapeutic amount of albiflorin in the immunotherapy for cancer comorbid with depression, cancer immunopotentiation therapy, and a method for improving the survival quality of cancer patients. Albiflorin (paeoniflorin), or a pharmaceutically acceptable salt thereof, or an extract or a pharmaceutical composition containing a therapeutic amount of albiflorin (paeoniflorin) serves as a potentiator of cancer immunotherapy. By means of multiple mechanisms for resisting chronic stress, relieving emotional distress, regulating circadian rhythm, mitigating intestinal flora disequilibrium, inhibiting overactivation of IDO1, and correcting metabolic abnormalities, treatment of cancer comorbid with depression is potentiated synergistically, especially the immunotherapy for cancer comorbid with depression.

The invention provides methods and related compositions for preventing neurocognitive decline associated with chronic stress, age, and neurodegenerative diseases. The methods described here are based upon the use of alpha5-GABAA receptor agonists to slow or prevent deleterious morphological changes in dendrites of the hippocampus and prefrontal cortex, which eventually manifest in functional decline and the neurocognitive deficits.

Pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) antagonist / inhibitor are described for use in methods of treating, ameliorating or preventing mood disorders / affective disorders and / or chronic stress and / or anxiety disorders and / or Parkinson's disease. Furthermore, pharmaceutical compositions comprising a neuropeptide B / W receptor (NPBWR1) agonist / activator are described for use in methods of treating, ameliorating or preventing bipolar disorder manic (ICD-10 F31), appetite disorders, preferably anorexia or bulimia. Furthermore, a method of assessing the activity of a candidate molecule suspected to be a NPBWR1 antagonist / inhibitor or agonist / activator is described.

The invention discloses a probiotic medicinal and edible medicinal material composition as well as a preparation method and application thereof. The composition comprises combined probiotics and medicinal and edible medicinal materials, the combined probiotics comprise Lactobacillus plantarum JY001 and Lactobacillus plantarum JY002, and the medicinal and edible medicinal materials comprise cistanche deserticola, semen raphani, peach kernels, astragalus membranaceus, codonopsis pilosula and pericarpium citri reticulatae. The composition takes medicinal and edible medicinal materials as raw materials, has the effect of improving endocrine hormone disorder caused by chronic stress after being fermented by combined probiotics, and can be applied to preparation of products for improving endocrine hormone disorder caused by chronic stress; the composition is especially applied to preparation of products for reversing reduction of thyroid stimulating hormone release hormone, adrenocorticotropic hormone and / or testosterone secretion level caused by chronic stress, and meanwhile, the composition also meets the requirements of people for resisting fatigue and improving constipation due to intestinal dryness.